StockData
Johnson & Johnson logo

Johnson & Johnson (JNJ) operating KPIs

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)

Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%

Johnson & Johnson zYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — Worldwide reported growth YoY (%) (%)

Form 8-K EX-99.2 Segment Sales Schedule

QuarterlyAnnual
Latest, Q4 2025
-11.9%
Period ended Dec 28, 2025
Change on a year earlier
+20.5 pts
-32.4% in Q4 2024
History
33 quarters
Since Q4 2017
Sources
33
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — Worldwide reported growth YoY (%) (%)Year on yearSource
Q4 2025Dec 28, 2025-11.9%+20.5 ptsForm 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗
Q3 2025Sep 28, 2025-25.1%+4.9 ptsForm 8-K (a2025q3exhibit991.htm, filed 2025-10-14) ↗
Q2 2025Jun 29, 2025-11.6%+16.1 ptsForm 8-K (a2025q2exhibit991.htm, filed 2025-07-16) ↗
Q1 2025Mar 30, 2025-30.9%-5.0 ptsForm 8-K (a2025q1exhibit991.htm, filed 2025-04-15) ↗
Q4 2024Dec 29, 2024-32.4%-6.8 ptsForm 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗
Q3 2024Sep 29, 2024-30.0%+23.0 ptsForm 8-K (a2024q3exhibit991.htm, filed 2024-10-15) ↗
Q2 2024Jun 30, 2024-27.7%+27.4 ptsForm 8-K (a2024q2exhibit991.htm, filed 2024-07-17) ↗
Q1 2024Mar 31, 2024-25.9%+28.6 ptsForm 8-K (a2024q1exhibit991.htm, filed 2024-04-16) ↗
Q4 2023Dec 31, 2023-25.6%+25.2 ptsForm 8-K (a2023q4exhibit991.htm, filed 2024-01-23) ↗
Q3 2023Oct 1, 2023-53.0%-36.3 ptsForm 8-K (a2023q3exhibit991.htm, filed 2023-10-17) ↗
Q2 2023Jul 2, 2023-55.1%-44.8 ptsForm 8-K (a2023q2exhibit991.htm, filed 2023-07-20) ↗
Q1 2023Apr 2, 2023-54.5%-38.9 ptsForm 8-K (a2023q1exhibit991.htm, filed 2023-04-18) ↗
Q4 2022Jan 1, 2023-50.8%-39.0 ptsForm 8-K (a2022q4exhibit991.htm, filed 2023-01-24) ↗
Q3 2022Oct 2, 2022-16.7%-9.5 ptsForm 8-K (a2022q3exhibit991.htm, filed 2022-10-18) ↗
Q2 2022Jul 3, 2022-10.3%-9.5 ptsForm 8-K (a2022q2exhibit991.htm, filed 2022-07-19) ↗
Q1 2022Apr 3, 2022-15.6%-8.0 ptsForm 8-K (a2022q1exhibit991.htm, filed 2022-04-19) ↗

Cite this data

StockData. (2026). Johnson & Johnson ZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — Worldwide reported growth YoY (%) (%), quarterly Q4 2017–Q4 2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug_zytiga_rep_yoy

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.